{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T05:05:11Z","timestamp":1755839111966,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T00:00:00Z","timestamp":1616976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T00:00:00Z","timestamp":1616976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2020ZX09201022"],"award-info":[{"award-number":["2020ZX09201022"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s13318-021-00682-4","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T10:03:18Z","timestamp":1617012198000},"page":"427-436","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacokinetics of Eltrombopag in Healthy Chinese Subjects and Effect of Sex and Genetic Polymorphism on its Pharmacokinetic and Pharmacodynamic Variability"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7981-0510","authenticated-orcid":false,"given":"Jinliang","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yichao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honggang","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zourong","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"issue":"11","key":"682_CR1","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","volume":"113","author":"F Rodeghiero","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386\u201393. https:\/\/doi.org\/10.1182\/blood-2008-07-162503.","journal-title":"Blood"},{"issue":"3","key":"682_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/0091270010368677","volume":"51","author":"G Matthys","year":"2011","unstructured":"Matthys G, Park JW, McGuire S, Wire MB, Bowen C, Williams D, et al. Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers. J Clin Pharmacol. 2011;51(3):301\u20138. https:\/\/doi.org\/10.1177\/0091270010368677.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"682_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s13318-018-0490-x","volume":"44","author":"MI Saleh","year":"2019","unstructured":"Saleh MI, Melhim SB, Al-Ramadhani HM, Alzubiedi S. Bayesian population pharmacokinetic modeling of eltrombopag in chronic hepatitis C patients. Eur J Drug Metab Pharmacokinet. 2019;44(1):31\u201342. https:\/\/doi.org\/10.1007\/s13318-018-0490-x.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"11","key":"682_CR4","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.clinthera.2011.10.004","volume":"33","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Kolesar JM. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura. Clin Ther. 2011;33(11):1560\u201376. https:\/\/doi.org\/10.1016\/j.clinthera.2011.10.004.","journal-title":"Clin Ther"},{"issue":"3","key":"682_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00228-019-02822-x","volume":"76","author":"M Karazniewicz-Lada","year":"2020","unstructured":"Karazniewicz-Lada M, Krzyzanska D, Danielak D, Rzezniczak J, Glowka F, Slomczynski M, et al. Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatin. Eur J Clin Pharmacol. 2020;76(3):419\u201330. https:\/\/doi.org\/10.1007\/s00228-019-02822-x.","journal-title":"Eur J Clin Pharmacol"},{"key":"682_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12774","author":"U Schilling","year":"2020","unstructured":"Schilling U, Dingemanse J, Voors-Pette C, Romeijn C, Dogterom P, Ufer M. Effect of rifampin-mediated OATP1B1 and OATP1B3 transporter inhibition on the pharmacokinetics of the P2Y12 receptor antagonist selatogrel. Clin Transl Sci. 2020. https:\/\/doi.org\/10.1111\/cts.12774.","journal-title":"Clin Transl Sci"},{"issue":"10","key":"682_CR7","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1177\/0091270010383019","volume":"51","author":"S Hayes","year":"2011","unstructured":"Hayes S, Ouellet D, Zhang J, Wire MB, Gibiansky E. Population PK\/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing. J Clin Pharmacol. 2011;51(10):1403\u201317. https:\/\/doi.org\/10.1177\/0091270010383019.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"682_CR8","doi-asserted-by":"publisher","first-page":"616","DOI":"10.2133\/dmpk.dmpk-10-sc-051","volume":"25","author":"JS Lim","year":"2010","unstructured":"Lim JS, Singh O, Ramasamy RD, Ramasamy S, Subramanian K, Lee EJ, et al. Pharmacogenetics of CYP1A2, novel polymorphisms and haplotypes in three distinct Asian populations. Drug Metab Pharmacokinet. 2010;25(6):616\u201323. https:\/\/doi.org\/10.2133\/dmpk.dmpk-10-sc-051.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"3","key":"682_CR9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000209851","volume":"96","author":"YY Zhou","year":"2009","unstructured":"Zhou YY, Lee LY, Ng SY, Hia CP, Low KT, Chong YS, et al. UGT1A1 haplotype mutation among Asians in Singapore. Neonatology. 2009;96(3):150\u20135. https:\/\/doi.org\/10.1159\/000209851.","journal-title":"Neonatology"},{"issue":"6","key":"682_CR10","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1128\/AAC.05214-11","volume":"56","author":"MB Wire","year":"2012","unstructured":"Wire MB, McLean HB, Pendry C, Theodore D, Park JW, Peng B. Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir\u2013ritonavir in healthy adult subjects. Antimicrob Agents Chemother. 2012;56(6):2846\u201351. https:\/\/doi.org\/10.1128\/AAC.05214-11.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"682_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1365-2125.2011.03972.x","volume":"72","author":"AJ Allred","year":"2011","unstructured":"Allred AJ, Bowen CJ, Park JW, Peng B, Williams DD, Wire MB, et al. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers. Br J Clin Pharmacol. 2011;72(2):321\u20139. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.03972.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"682_CR12","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.clinthera.2009.04.010","volume":"31","author":"DD Williams","year":"2009","unstructured":"Williams DD, Peng B, Bailey CK, Wire MB, Deng Y, Park JW, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther. 2009;31(4):764\u201376. https:\/\/doi.org\/10.1016\/j.clinthera.2009.04.010.","journal-title":"Clin Ther"},{"issue":"1","key":"682_CR13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3999\/jscpt.42.11","volume":"42","author":"S Yuri","year":"2011","unstructured":"Yuri S, Shigeru N, Toshiyasu H. Pharmacokinetics and pharmacodynamics of eltrombopag in healthy Japanese males. Jpn J Clin Pharmacol Ther. 2011;42(1):11\u201320.","journal-title":"Jpn J Clin Pharmacol Ther"},{"issue":"7","key":"682_CR14","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.clinthera.2015.03.024","volume":"37","author":"K Wu","year":"2015","unstructured":"Wu K, Thapar M, Farrell C, Hayes S, Guo H, Hou M, et al. Population pharmacokinetic and pharmacodynamic modeling and effects on platelet counts of different dosages of eltrombopag in Chinese patients with chronic primary immune thrombocytopenia. Clin Ther. 2015;37(7):1382\u201395. https:\/\/doi.org\/10.1016\/j.clinthera.2015.03.024.","journal-title":"Clin Ther"},{"issue":"5","key":"682_CR15","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1742-7843.2005.pto_01.x","volume":"96","author":"M Durisova","year":"2005","unstructured":"Durisova M, Dedik L. New mathematical methods in pharmacokinetic modeling. Basic Clin Pharmacol Toxicol. 2005;96(5):335\u201342. https:\/\/doi.org\/10.1111\/j.1742-7843.2005.pto_01.x.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"5","key":"682_CR16","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/s0731-7085(99)00272-1","volume":"22","author":"S Agatonovic-Kustrin","year":"2000","unstructured":"Agatonovic-Kustrin S, Beresford R. Basic concepts of artificial neural network (ANN) modeling and its application in pharmaceutical research. J Pharm Biomed Anal. 2000;22(5):717\u201327. https:\/\/doi.org\/10.1016\/s0731-7085(99)00272-1.","journal-title":"J Pharm Biomed Anal"},{"issue":"5","key":"682_CR17","doi-asserted-by":"publisher","first-page":"856","DOI":"10.18433\/j33031","volume":"18","author":"M Jovanovic","year":"2015","unstructured":"Jovanovic M, Sokic D, Grabnar I, Vovk T, Prostran M, Eric S, et al. Application of counter-propagation artificial neural networks in prediction of topiramate concentration in patients with epilepsy. J Pharm Pharm Sci. 2015;18(5):856\u201362. https:\/\/doi.org\/10.18433\/j33031.","journal-title":"J Pharm Pharm Sci"},{"key":"682_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.809","author":"Y Xu","year":"2020","unstructured":"Xu Y, Lou H, Chen J, Jiang B, Yang D, Hu Y, et al. Application of a backpropagation artificial neural network in predicting plasma concentration and pharmacokinetic parameters of oral single-dose rosuvastatin in healthy subjects. Clin Pharmacol Drug Dev. 2020. https:\/\/doi.org\/10.1002\/cpdd.809.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"682_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-020-00647-z","author":"J Chen","year":"2020","unstructured":"Chen J, Xu Y, Lou H, Jiang B, Shao R, Yang D, et al. Effect of genetic polymorphisms on the pharmacokinetics of deferasirox in healthy Chinese subjects and an artificial neural networks model for pharmacokinetic prediction. Eur J Drug Metab Pharmacokinet. 2020. https:\/\/doi.org\/10.1007\/s13318-020-00647-z.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"682_CR20","unstructured":"1000Geneomes. http:\/\/www.ncbi.nlm.gov\/variation\/tools\/1000genomes\/."},{"issue":"8","key":"682_CR21","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1177\/1076029616663849","volume":"23","author":"AS Elgebaly","year":"2017","unstructured":"Elgebaly AS, Ashal GE, Elfil M, Menshawy A. Tolerability and efficacy of eltrombopag in chronic immune thrombocytopenia: meta-analysis of randomized controlled trials. Clin Appl Thromb Hemostasis. 2017;23(8):928\u201337. https:\/\/doi.org\/10.1177\/1076029616663849.","journal-title":"Clin Appl Thromb Hemostasis"},{"issue":"4","key":"682_CR22","doi-asserted-by":"publisher","first-page":"E267","DOI":"10.1002\/ajh.24310","volume":"91","author":"F Palandri","year":"2016","unstructured":"Palandri F, Polverelli N, Sollazzo D, Romano M, Catani L, Cavo M, et al. Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years. Am J Hematol. 2016;91(4):E267\u201372. https:\/\/doi.org\/10.1002\/ajh.24310.","journal-title":"Am J Hematol"},{"issue":"23","key":"682_CR23","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","volume":"130","author":"RSM Wong","year":"2017","unstructured":"Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, et al. Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130(23):2527\u201336. https:\/\/doi.org\/10.1182\/blood-2017-04-748707.","journal-title":"Blood"},{"issue":"3","key":"682_CR24","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.clinthera.2012.01.011","volume":"34","author":"MB Wire","year":"2012","unstructured":"Wire MB, Bruce J, Gauvin J, Pendry CJ, McGuire S, Qian Y, et al. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 h before or after PfOS. Clin Ther. 2012;34(3):699\u2013709. https:\/\/doi.org\/10.1016\/j.clinthera.2012.01.011.","journal-title":"Clin Ther"},{"issue":"9","key":"682_CR25","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1517\/17425255.2013.795540","volume":"9","author":"V Perera","year":"2013","unstructured":"Perera V, Gross AS, Polasek TM, Qin Y, Rao G, Forrest A, et al. Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia. Expert Opin Drug Metab Toxicol. 2013;9(9):1115\u201337. https:\/\/doi.org\/10.1517\/17425255.2013.795540.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"682_CR26","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1017\/S0007114518000260","volume":"119","author":"TM Robertson","year":"2018","unstructured":"Robertson TM, Clifford MN, Penson S, Williams P, Robertson MD. Postprandial glycaemic and lipaemic responses to chronic coffee consumption may be modulated by CYP1A2 polymorphisms. Br J Nutr. 2018;119(7):792\u2013800. https:\/\/doi.org\/10.1017\/S0007114518000260.","journal-title":"Br J Nutr"},{"issue":"1","key":"682_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/FPC.0b013e32834c6efd","volume":"22","author":"CF Thorn","year":"2012","unstructured":"Thorn CF, Aklillu E, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for CYP1A2. Pharmacogenet Genomics. 2012;22(1):73\u20137. https:\/\/doi.org\/10.1097\/FPC.0b013e32834c6efd.","journal-title":"Pharmacogenet Genomics"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-021-00682-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-021-00682-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-021-00682-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T20:36:20Z","timestamp":1620074180000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-021-00682-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,29]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["682"],"URL":"https:\/\/doi.org\/10.1007\/s13318-021-00682-4","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"type":"print","value":"0378-7966"},{"type":"electronic","value":"2107-0180"}],"subject":[],"published":{"date-parts":[[2021,3,29]]},"assertion":[{"value":"10 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JC: designed and conceived the study, analyzed the data, wrote the original manuscript; ZR: designed and conceived the study, and provided the pharmacokinetics analysis; HL, BJ, RS, DY, YX, and YH: conceived the study. All authors were involved in reviewing the manuscript and approved the final version.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This study was supported by the National Major Science and Technology Projects of China (no. 2020ZX09201022).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors (JC, YX, HL, BJ, RS, DY, YH, and ZR) declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol and amendment of the study were reviewed and approved by the Human Subject Research Ethics Committee of the Second Affiliated Hospital of Zhejiang University School of Medicine (Hangzhou, Zhejiang, China). This study, which is registered at  (CTR20190898), was conducted at the Phase I Clinical Trials Unit of the Second Affiliated Hospital of Zhejiang University School of Medicine in accordance with Good Clinical Practices and the ethical principles of the amended Declaration of Helsinki (revised version of Fortaleza, 2013). Documented written informed consent was obtained from each subject before any protocol-related investigations or procedures.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Documented written informed consent was obtained from each subject before any protocol-related investigations or procedures.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}